Serum IL-34 and IL-17A as novel biomarkers for diabetic retinopathy in type 2 diabetes: A cross-sectional study
Authors:
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Heilongjiang Province (LH2023H024)
This publication has 15 references indexed in Scilit:
- IL-34 is expressed in the pancreas and regulates local inflammationTranslational Research, 2025
- IL-34 aggravates myocardial ischemia-reperfusion injury by upregulating the HMGB1-IL-17A-IL-6 axis through the JAK signaling pathwayPLOS ONE, 2025
- Interleukin-17A in diabetic retinopathy: The crosstalk of inflammation and angiogenesisBiochemical Pharmacology, 2024
- Role of IL-34 and its receptors in inflammatory diseasesCytokine, 2023
- Effect of IL-34 on T helper 17 cell proliferation and IL-17 secretion by peripheral blood mononuclear cells from rheumatoid arthritis patientsScientific Reports, 2020
- IL-34 causes inflammation and beta cell apoptosis and dysfunction in gestational diabetes mellitusEndocrine Connections, 2019
- The cut-off value for interleukin 34 as an additional potential inflammatory biomarker for the prediction of the risk of diabetic complicationsBiomarkers, 2016
- IL-34 Is Associated with Obesity, Chronic Inflammation, and Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2014
- IL-17 family: Cytokines, receptors and signalingCytokine, 2013
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012